We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Avoid Investing in Danaher Stock Right Now
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) has failed to impress investors with its recent operational performance due to softness in the Life Sciences segment. Also, increasing expenses are likely to impede the company’s earnings in the quarters ahead.
Danaher is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. It is headquartered in Washington, DC.
DHR currently carries a Zacks Rank #4 (Sell). In the past year, the stock has gained 6.6% against the industry’s 6.5% decline.
Image Source: Zacks Investment Research
Let’s discuss the factors, which are likely to continue taking a toll on this company.
Segment Weakness: Weakness in Danaher’s Instrument businesses, led by lower demand across pharma and biotech markets in China, has been weighing on the Life Sciences segment. The company has been witnessing a sales decline in mass spectrometry, flow cytometry & lab automation solutions and microscopy businesses due to soft demand for equipment in major end markets. Softness in the genomics consumables business, owing to tepid sales in the gene reading and proteins product lines, remains concerning for the segment.
Also, weakness in the Biotechnology segment raises concerns for the company. Decreased demand in the discovery and medical business has been weighing on the performance of the Biotechnology segment.
Increasing Expenses: Danaher has been dealing with the adverse impacts of high costs and expenses. The company’s selling, general and administrative (SG&A) expenses increased 19.2% year over year in the third quarter of 2024 due to the impact of the Abcam acquisition, including the associated amortization expense. The metric, as a percentage of net sales, increased 480 basis points to 35.5% in the quarter. Also, it's worth noting that in 2023, its SG&A expenses, as a percentage of net sales, increased 400 basis points to 30.7%.
Forex Woes: Danaher has operations in multiple nations. Such business diversifications expose it to risks stemming from unfavorable movements in foreign currencies, geopolitical issues and other headwinds. Forex woes had an adverse impact of 1% on the company’s revenue growth in the first nine months of 2024.
FSS delivered a trailing four-quarter average earnings surprise of 11.8%. In the past 60 days, the Zacks Consensus Estimate for Federal Signal’s 2024 earnings has increased 3.1%.
Zurn Elkay Water Solutions Corporation (ZWS - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 8.5%.
In the past 60 days, the Zacks Consensus Estimate for ZWS’ 2024 earnings has increased 2.5%.
RBC Bearings Incorporated (RBC - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 2.5%.
In the past 60 days, the consensus estimate for RBC’s fiscal 2025 earnings has increased 0.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Avoid Investing in Danaher Stock Right Now
Danaher Corporation (DHR - Free Report) has failed to impress investors with its recent operational performance due to softness in the Life Sciences segment. Also, increasing expenses are likely to impede the company’s earnings in the quarters ahead.
Danaher is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. It is headquartered in Washington, DC.
DHR currently carries a Zacks Rank #4 (Sell). In the past year, the stock has gained 6.6% against the industry’s 6.5% decline.
Image Source: Zacks Investment Research
Let’s discuss the factors, which are likely to continue taking a toll on this company.
Segment Weakness: Weakness in Danaher’s Instrument businesses, led by lower demand across pharma and biotech markets in China, has been weighing on the Life Sciences segment. The company has been witnessing a sales decline in mass spectrometry, flow cytometry & lab automation solutions and microscopy businesses due to soft demand for equipment in major end markets. Softness in the genomics consumables business, owing to tepid sales in the gene reading and proteins product lines, remains concerning for the segment.
Also, weakness in the Biotechnology segment raises concerns for the company. Decreased demand in the discovery and medical business has been weighing on the performance of the Biotechnology segment.
Increasing Expenses: Danaher has been dealing with the adverse impacts of high costs and expenses. The company’s selling, general and administrative (SG&A) expenses increased 19.2% year over year in the third quarter of 2024 due to the impact of the Abcam acquisition, including the associated amortization expense. The metric, as a percentage of net sales, increased 480 basis points to 35.5% in the quarter. Also, it's worth noting that in 2023, its SG&A expenses, as a percentage of net sales, increased 400 basis points to 30.7%.
Forex Woes: Danaher has operations in multiple nations. Such business diversifications expose it to risks stemming from unfavorable movements in foreign currencies, geopolitical issues and other headwinds. Forex woes had an adverse impact of 1% on the company’s revenue growth in the first nine months of 2024.
Stocks to Consider
Better-ranked companies are discussed below.
Federal Signal Corporation (FSS - Free Report) presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
FSS delivered a trailing four-quarter average earnings surprise of 11.8%. In the past 60 days, the Zacks Consensus Estimate for Federal Signal’s 2024 earnings has increased 3.1%.
Zurn Elkay Water Solutions Corporation (ZWS - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 8.5%.
In the past 60 days, the Zacks Consensus Estimate for ZWS’ 2024 earnings has increased 2.5%.
RBC Bearings Incorporated (RBC - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 2.5%.
In the past 60 days, the consensus estimate for RBC’s fiscal 2025 earnings has increased 0.5%.